



RESEARCH CONFERENCES

ESF-UB Conference in Biomedicine

Pharmacogenetics and Pharmacogenomics: Adverse Drug Reactions

Hotel Eden Roc, Sant Feliu de Guixols (Costa Brava) •
Spain

27 June – 2 July 2008

Chair: **Munir Pirmohamed**, University of Liverpool, UK
Vice-Chair: **Laurent Becquemont**, University Paris Sud,
FR

www.esf.org/conferences/08269

With support from



Generalitat de Catalunya
Departament d'Innovació,
Universitats i Empresa
**Comissionat per a Universitats
i Recerca**



Final Programme

Friday 27 June

Late afternoon / early evening	Registration at the ESF-RC desk
19.00	Welcome Drink
20.00	Dinner

Saturday 28 June

08.45-09.00	Munir Pirmohamed The University of Liverpool, UK <i>Conference Opening</i>
09.00-09.15	On behalf of the European Science Foundation Isabel Varela-Nieto Consejo Superior de Investigaciones Cientificas, Madrid, ES

Session 1: General Aspects of Adverse Drug Reactions

Chair: **Munir Pirmohamed**, The University of Liverpool, UK

09.15-10.15	Plenary Lecture 1 Alasdair Breckenridge MHRA, London, UK <i>Adverse Reactions. Epidemiology, clinical and regulatory perspectives</i>
10.15-10.45	Phillipe Beaune INSERM U775, Paris, FR <i>Role of drug metabolism in ADRs</i>
10.45-11.15	Coffee Break
11.15-11.45	Dietrich Keppler German Cancer Research Center (DKFZ), Heidelberg, DE <i>Role of transporters in ADRs</i>
11.45-12.15	Dean Naisbitt University of Liverpool, UK <i>The role of the immune system in ADRs</i>
12.15-12.30	May Fakhoury (short talk) University Paris VII - Bichat - Saint-Louis, FR <i>GENDRUG Network : Pharmacogenetics and Adverse Drug Reactions</i>
12.30	Lunch
16.00-16.30	Coffee Break

Session 2: Randomised Controlled Trials in Safety Pharmacogenetics

Chair: **Laurent Becquemont**, University Paris Sud, FR

16.30-17.00	Arlene Hughes GlaxoSmithKline, Research Triangle Park, US <i>Abacavir hypersensitivity: a paradigm for clinical implementation of pharmacogenetics?</i>
17.00-17.30	Bill Newman University of Manchester, UK <i>RCT of TPMT testing for azathioprine</i>

17.30-18.00	Yoseph Caraco Hadassah University Hospital, Jerusalem, IL <i>Warfarin pharmacogenetics: testing the paradigm of personalized medicine through RCT</i>
19.00	Dinner
20.30-22.00	Poster Session

Sunday 29 June

Session 3: Ethical, Legal and Social Issues in Safety Pharmacogenetics

Chair: **Geoff Tucker**, University of Sheffield, UK

09.00-10.00	Plenary Lecture 2 Ron van Schaik Erasmus MC, Rotterdam, NL <i>Implementation of pharmacogenetic testing into clinical practice: standards, opportunities and challenges</i>
10.00-10.30	Dyfrig Hughes University of Bangor, UK <i>Cost-effectiveness considerations in pharmacogenetics</i>
10.30-11.00	Coffee Break
11.00-11.30	Jeantine Lunshof VU University, Amsterdam, NL <i>Ethical issues in pharmacogenetics: informed consent</i>
11.30-11.45	Petra Bohanec Grabar (short talk) University of Ljubljana, SI <i>Genetic determinants of methotrexate induced adverse effects in rheumatoid arthritis patients</i>
11.45-12.00	Ursula Amstutz (short talk) University of Bern, CH <i>Old suspects and new culprits in 5-fluorouracil pharmacogenetics: Novel insights from a haplotype-based analysis of the dihydropyrimidine dehydrogenase gene</i>
12.00-12.15	Daniela Caronia (short talk) Spanish National Cancer Center, Madrid, ES <i>Cytidine deaminase polymorphisms are associated with hand-foot syndrome in Capecitabine-treated breast and colorectal cancer patients</i>
12.30	Lunch
15.45-16.15	Coffee Break

Session 4: Bioinformatics

Chair: **Laurent Becquemont**, University Paris Sud, FR

16.15-17.00	Frédéric Tores IntegraGen, Evry, FR <i>How to use genetic databases: focus on HapMap website</i>
17.00-17.45	Philippe Broët University Paris-Sud, Villejuif, FR <i>Multiple comparison procedures: applications to microarray phenotype-genotype analysis</i>
17.45-18.30	David Tregouet INSERM UMR S 525, Paris, FR <i>SNP & haplotype information in pharmacogenetic studies</i>
19.00	Dinner
20.00-21.30	Poster Session

Monday 30 June

Session 5: Whole Genome Association Studies

Chair: **Duncan McHale**, AstraZeneca Ltd, UK

09.00-10.00	Plenary Lecture 3 Duncan McHale AstraZeneca Ltd, UK <i>Using pharmacogenetics to understand rare idiosyncratic adverse events - the need for large consortia</i>
10.00-10.30	Nicole Soranzo The Wellcome Trust Sanger Institute, Hinxton, UK <i>Analysis of whole genome association studies - challenges and opportunities</i>
10.30-11.00	Coffee Break
11.00-11.30	Gianpiero Cavalleri Royal College of Surgeons (RCSI), Dublin, IE <i>Whole genome association in epilepsy predisposition and treatment</i>
11.30-12.00	Panos Deloukas The Wellcome Trust Sanger Institute, Hinxton, UK <i>Warfarin pharmacogenomics: lessons from genome wide association studies</i>
12.00-12.15	Fiona Brew (short talk) Affymetrix UK Ltd., High Wycombe, UK <i>A genetic variant of Cyp4F2 alters required Warfarin dose</i>
12.15-12.30	Andrea Jorgensen (short talk) University of Liverpool, UK <i>Genetic and environmental factors determining clinical outcomes associated with Warfarin therapy: a prospective study</i>
12.30	Lunch
Afternoon	Half-day Excursion to Girona
19.30	Dinner

Tuesday 1 July

Session 6: Pharmacogenetics of Organ-Based Adverse Drug Reactions

Chair: **Marcal Pastor Anglada**, University of Barcelona, ES

09.00-09.30	Raul Andrade University of Malaga, ES <i>Drug-induced liver injury: insights from genetic studies</i>
09.30-10.00	Hans F. Merk RWTH Aachen University, DE <i>Pharmacogenetics of serious cutaneous adverse drug reactions</i>
10.00-10.30	Ingolf Cascorbi University Hospital Schleswig-Holstein (UK-SI), Kiel, DE <i>HLA associations in clozapine agranulocytosis</i>
10.30-11.00	Coffee Break
11.00-11.30	Andrew Somogyi University of Adelaide, AU <i>Pharmacogenomic insights into addiction as an adverse drug reaction</i>
11.30-11.45	Ann Daly (short talk) Newcastle University, UK <i>Relationship of HLA class II genotype to susceptibility to antimicrobial-induced liver injury</i>

- 11.45-12.00 **Martin Armstrong** (short talk)
AstraZeneca, Macclesfield, UK
Assessing impact of genetic variability on pre-clinical screening strategies: pharmacological characterisation of human ether-a-go-go-related (hERG) gene-encoded potassium channel variants
- 12.00-12.15 **Ana Alfirevic** (short talk)
The University of Liverpool, UK
Major histocompatibility complex (MHC) genetic polymorphisms in patients with hypersensitivity to carbamazepine
- 12.30 Lunch
- 16.00-16.30 Coffee Break

Session 7: Debate - Pharmacogenetic testing will have a minor role in drug treatment

Chair: **Phillipe Beaune**, INSERM U775, Paris, FR

- 16.30-16.45 **Geoff Tucker**
University of Sheffield, UK
For the motion
- 16.45-17.00 **Michel Eichelbaum**
Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP), Stuttgart, DE
Against the motion
- 17.10-17.45 Discussion, closing arguments and vote
- 17.45-18.30 Business Meeting
- 19.30 Get-together & Conference Dinner

Wednesday 2 July

Session 8: New Technologies in Studying and Preventing ADRs

Chair: **Munir Pirmohamed**, The University of Liverpool, UK

- 09.00-10.00 **Plenary Lecture 4**
Neil Hall
The University of Liverpool, UK
High throughput sequencing technologies and their potential role in genetics and pharmacogenetics
- 10.00-10.30 Coffee Break
- 10.30-11.15 **Juan Pablo Albar**
Centro Nacional de Biotecnología, Madrid, ES
Proteomics: how it could be utilised in ADR research
- 11.15-12.00 **Bernard Walther**
Servier, Orléans, FR
Metabolomics as a complementary tool in global systems approaches
- 12.00 Lunch & Departure

Abstracts, Posters & Short Oral Presentations

There will be no short talks other than those listed in the programme.
All abstracts submitted are accepted for poster presentation.